1290 related articles for article (PubMed ID: 24137577)
41. Autoimmune lymphoproliferative syndrome and non-Hodgkin lymphoma: what 18F-fluorodeoxyglucose positron emission tomography/computed tomography can do in the management of these patients? Suggestions from a case report.
Cistaro A; Pazè F; Durando S; Cogoni M; Faletti R; Vesco S; Vallero S; Quartuccio N; Treglia G; Ramenghi U
Rev Esp Med Nucl Imagen Mol; 2014; 33(2):99-102. PubMed ID: 23845452
[TBL] [Abstract][Full Text] [Related]
42. The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma.
Bhojwani D; McCarville MB; Choi JK; Sawyer J; Metzger ML; Inaba H; Davidoff AM; Gold R; Shulkin BL; Sandlund JT
Br J Haematol; 2015 Mar; 168(6):845-53. PubMed ID: 25382494
[TBL] [Abstract][Full Text] [Related]
43. FDG PET/CT in the management of colorectal and anal cancers.
Agarwal A; Marcus C; Xiao J; Nene P; Kachnic LA; Subramaniam RM
AJR Am J Roentgenol; 2014 Nov; 203(5):1109-19. PubMed ID: 25341152
[TBL] [Abstract][Full Text] [Related]
44. 18F-FDG-PET/CT better localizes active spinal infection than MRI for successful minimally invasive surgery.
Nakahara M; Ito M; Hattori N; Magota K; Takahata M; Nagahama K; Sudo H; Kamishima T; Tamaki N; Iwasaki N
Acta Radiol; 2015 Jul; 56(7):829-36. PubMed ID: 25080515
[TBL] [Abstract][Full Text] [Related]
45. 18F-FDG PET in malignant lymphoma: significance of positive findings.
Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
[TBL] [Abstract][Full Text] [Related]
46. FDG PET/MR for the assessment of lymph node involvement in lymphoma: initial results and role of diffusion-weighted MR.
Platzek I; Beuthien-Baumann B; Ordemann R; Maus J; Schramm G; Kitzler HH; Laniado M; Kotzerke J; van den Hoff J
Acad Radiol; 2014 Oct; 21(10):1314-9. PubMed ID: 25086953
[TBL] [Abstract][Full Text] [Related]
47. Determination of vitality of liver lesions by alveolar echinococcosis. Comparison of parametric contrast enhanced ultrasound (SonoVue®) with quantified 18F-FDG-PET-CT.
Kaltenbach TE; Graeter T; Mason RA; Kratzer W; Oeztuerk S; Haenle MM; Gruener B; Gottstein M
Nuklearmedizin; 2015; 54(1):43-9. PubMed ID: 25423884
[TBL] [Abstract][Full Text] [Related]
48. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
[TBL] [Abstract][Full Text] [Related]
49. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
[TBL] [Abstract][Full Text] [Related]
50. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging.
Lopci E; Burnelli R; Ambrosini V; Nanni C; Castellucci P; Biassoni L; Rubello D; Fanti S
Cancer Biother Radiopharm; 2008 Dec; 23(6):681-90. PubMed ID: 19111053
[TBL] [Abstract][Full Text] [Related]
51. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma.
Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P
Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087
[TBL] [Abstract][Full Text] [Related]
52. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
53. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
54. FDG-PET/CT in lymphoma.
Juweid ME
Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
[TBL] [Abstract][Full Text] [Related]
55. 18F-FDG-PET/CT in fever of unknown origin: clinical value.
Buch-Olsen KM; Andersen RV; Hess S; Braad PE; Schifter S
Nucl Med Commun; 2014 Sep; 35(9):955-60. PubMed ID: 24801131
[TBL] [Abstract][Full Text] [Related]
56. Bone involvement in patients with lymphoma: the role of FDG-PET/CT.
Schaefer NG; Strobel K; Taverna C; Hany TF
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):60-7. PubMed ID: 17021808
[TBL] [Abstract][Full Text] [Related]
57. ¹⁸F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas.
Eugene T; Corradini N; Carlier T; Dupas B; Leux C; Bodet-Milin C
Nucl Med Commun; 2012 Oct; 33(10):1089-95. PubMed ID: 22929116
[TBL] [Abstract][Full Text] [Related]
58. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
Chiusolo P; Sica S; Leone G
Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
[TBL] [Abstract][Full Text] [Related]
59. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
Ömür Ö; Baran Y; Oral A; Ceylan Y
Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817
[TBL] [Abstract][Full Text] [Related]
60. Imaging by ¹⁸F-FDG PET/CT of diffuse large B-cell lymphoma with cellulitis.
Zhang Y; Li B; Cai L; Shi H; Hou J
Hell J Nucl Med; 2015; 18(3):271-2. PubMed ID: 26574700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
